Table of Contents Author Guidelines Submit a Manuscript
Malaria Research and Treatment
Volume 2012, Article ID 679090, 12 pages
http://dx.doi.org/10.1155/2012/679090
Research Article

Artesunate Exerts a Direct Effect on Endothelial Cell Activation and NF- B Translocation in a Mechanism Independent of Plasmodium Killing

1Laboratório de Farmacologia Aplicada, Departamento de Farmacologia Aplicada, Farmanguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, Manguinhos, 21041-250 Rio de Janeiro, RJ, Brazil
2Laboratório de Educação Profissional em Técnicas Laboratoriais em Saúde, Escola Politécnica de Saúde Joaquim Venâncio, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
3Drugs for Neglected Diseases Initiative, Geneva, Switzerland

Received 30 May 2012; Revised 16 August 2012; Accepted 30 August 2012

Academic Editor: Mats Wahlgren

Copyright © 2012 Mariana C. Souza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. J. Woodrow, R. K. Haynes, and S. Krishna, “Artemisinins,” Postgraduate Medical Journal, vol. 81, no. 952, pp. 71–78, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Maude, C. J. Woodrow, and L. J. White, “Artemisinin antimalarials: preserving the “magic bullet”,” Drug Development Research, vol. 71, no. 1, pp. 12–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Efferth, H. Dunstan, A. Sauerbrey, H. Miyachi, and C. R. Chitambar, “The anti-malarial artesunate is also active against cancer,” International Journal of Oncology, vol. 18, no. 4, pp. 767–773, 2001. View at Google Scholar · View at Scopus
  4. S. J. F. Kaptein, T. Efferth, M. Leis et al., “The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo,” Antiviral Research, vol. 69, no. 2, pp. 60–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Mirshafiey, F. Saadat, M. Attar, R. Di Paola, R. Sedaghat, and S. Cuzzocrea, “Design of a new line in treatment of experimental rheumatoid arthritis by artesunate,” Immunopharmacology and Immunotoxicology, vol. 28, no. 3, pp. 397–410, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. A. F. Tawfik, S. J. Bishop, A. Ayalp, and F. S. El-Feraly, “Effects of artemisinin, dihydroartemisinin and arteether on immune responses of normal mice,” International Journal of Immunopharmacology, vol. 12, no. 4, pp. 385–389, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Veerasubramanian, P. Gosi, C. Limsomwong, and D. S. Walsh, “Artesunate and a major metabolite, dihydroartemisinin, diminish MITOGEN-induced lymphocyte proliferation and activation,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 37, no. 5, pp. 838–847, 2006. View at Google Scholar · View at Scopus
  8. J. Wang, H. Zhou, J. Zheng et al., “The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Eschenchia coli challenge by decreasing proinflammatory cytokine release,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 7, pp. 2420–2427, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Xu, Y. He, X. Yang et al., “Anti-malarial agent artesunate inhibits TNF-α-induced production of proinflammatory cytokines via inhibition of NF-κB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes,” Rheumatology, vol. 46, no. 6, pp. 920–926, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Li, J. Li, X. Pan et al., “Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-α release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-κB activation,” International Immunopharmacology, vol. 10, no. 3, pp. 344–350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Cheng, W. E. Ho, F. Y. Goh et al., “Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway,” PLoS ONE, vol. 6, no. 6, Article ID e20932, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. H. C. van der Heyde, J. Nolan, V. Combes, I. Gramaglia, and G. E. Grau, “A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction,” Trends in Parasitology, vol. 22, no. 11, pp. 503–508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. B. de Souza, J. C. R. Hafalla, E. M. Riley, and K. N. Couper, “Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease,” Parasitology, vol. 137, no. 5, pp. 755–772, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. D. A. Fidock, P. J. Rosenthal, S. L. Croft, R. Brun, and S. Nwaka, “Antimalarial drug discovery: efficacy models for compound screening,” Nature Reviews Drug Discovery, vol. 3, no. 6, pp. 509–520, 2004. View at Google Scholar · View at Scopus
  15. L. Clemmer, Y. C. Martins, G. M. Zanini, J. A. Frangos, and L. J. M. Carvalho, “Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 4, pp. 1383–1390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. P. R. Bauer, H. C. van der Heyde, G. Sun, R. D. Specian, and D. N. Granger, “Regulation of endothelial cell adhesion molecule expression in an experimental model of cerebral malaria,” Microcirculation, vol. 9, no. 6, pp. 463–470, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. S. Desruisseaux, F. S. Machado, L. M. Weiss, H. B. Tanowitz, and L. M. Golightly, “Cerebral malaria: a vasculopathy,” American Journal of Pathology, vol. 176, no. 3, pp. 1075–1078, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. J. Janse, A. P. Waters, J. Kos, and C. B. Lugt, “Comparison of in vivo and in vitro antimalarial activity of artemisinin, dihydroartemisinin and sodium artesunate in the Plasmodium berghei-rodent model,” International Journal for Parasitology, vol. 24, no. 4, pp. 589–594, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. P. J. de Vries and T. K. Dien, “Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria,” Drugs, vol. 52, no. 6, pp. 818–836, 1996. View at Google Scholar · View at Scopus
  20. H. C. van der Heyde, P. Bauer, G. Sun et al., “Assessing vascular permeability during experimental cerebral malaria by a radiolabeled monoclonal antibody technique,” Infection and Immunity, vol. 69, no. 5, pp. 3460–3465, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Pamplona, A. Ferreira, J. Balla et al., “Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria,” Nature Medicine, vol. 13, no. 6, pp. 703–710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Roffê, A. A. Silva, A. P. M. P. Marino, P. V. A. dos Santos, and J. Lannes-Vieira, “Essential role of VLA-4/VCAM-1 pathway in the establishment of CD8+ T-cell-mediated Trypanosoma cruzi-elicited meningoencephalitis,” Journal of Neuroimmunology, vol. 142, no. 1-2, pp. 17–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. B. T. Walther, R. Ohman, and S. Roseman, “A quantitative assay for intercellular adhesion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 70, no. 5, pp. 1569–1573, 1973. View at Google Scholar · View at Scopus
  24. M. C. de Assis, M. C. Plotkowski, I. M. Fierro, C. Barja-Fidalgo, and M. S. de Freitas, “Expression of inducible nitric oxide synthase in human umbilical vein endothelial cells during primary culture,” Nitric Oxide, vol. 7, no. 4, pp. 254–261, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. N. K. Viebig, U. Wulbrand, R. Förster, K. T. Andrews, M. Lanzer, and P. A. Knolle, “Direct activation of human endothelial cells by Plasmodium falciparum-infected erythrocytes,” Infection and Immunity, vol. 73, no. 6, pp. 3271–3277, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Kamchonwongpaisan and S. R. Meshnick, “The mode of action of the antimalarial artemisinin and its derivatives,” General Pharmacology, vol. 27, no. 4, pp. 587–592, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. W. D. Li, Y. J. Dong, Y. Y. Tu, and Z. B. Lin, “Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-α and blocking the signaling pathway NF-κB translocation,” International Immunopharmacology, vol. 6, no. 8, pp. 1243–1250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Li, R. Zhang, J. Li et al., “Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-κB activation,” International Immunopharmacology, vol. 8, no. 3, pp. 379–389, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. F. G. Baptista, A. Pamplona, A. C. Pena, M. M. Mota, S. Pied, and A. M. Vigário, “Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice,” Infection and Immunity, vol. 78, no. 9, pp. 4033–4039, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. F. H. Amante, A. Haque, A. C. Stanley et al., “Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria,” Journal of Immunology, vol. 185, no. 6, pp. 3632–3642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Cabrales, G. M. Zanini, D. Meays, J. A. Frangos, and L. J. M. Carvalho, “Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology,” Journal of Infectious Diseases, vol. 203, no. 10, pp. 1454–1463, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. M. E. Sarciron, C. Saccharin, A. F. Petavy, and F. Peyron, “Effects of artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin combination against Toxoplasma gondii,” American Journal of Tropical Medicine and Hygiene, vol. 62, no. 1, pp. 73–76, 2000. View at Google Scholar · View at Scopus
  33. H. H. Chen, H. J. Zhou, G. D. Wu, and X. E. Lou, “Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1,” Pharmacology, vol. 71, no. 1, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Ohayon, J. Golenser, R. Sinay et al., “Protein kinase C θ deficiency increases resistance of C57BL/6J mice to Plasmodium berghei infection-induced cerebral malaria,” Infection and Immunity, vol. 78, no. 10, pp. 4195–4205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Favre, C. Da Laperousaz, B. Ryffel et al., “Role of ICAM-1 (CD54) in the development of murine cerebral malaria,” Microbes and Infection, vol. 1, no. 12, pp. 961–968, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Joergensen, D. C. Bengtsson, A. Bengtsson et al., “Surface co-expression of two different PfEMP1 antigens on single Plasmodium falciparum-infected erythrocytes facilitates binding to ICAM1 and PECAM1,” PLoS Pathogens, vol. 6, no. 9, Article ID e01083, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. D. A. Fedosov, B. Caswell, S. Suresh, and G. E. Karniadakis, “Quantifying the biophysical characteristics of Plasmodium-falciparum- parasitized red blood cells in microcirculation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 1, pp. 35–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Semmrich, A. Smith, C. Feterowski et al., “Importance of integrin LFA-1 deactivation for the generation of immune responses,” Journal of Experimental Medicine, vol. 201, no. 12, pp. 1987–1998, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. A. K. Tripathi, D. J. Sullivan, and M. F. Stins, “Plasmodium falciparum-infected erythrocytes increase intercellular adhesion molecule 1 expression on brain endothelium through NF-κB,” Infection and Immunity, vol. 74, no. 6, pp. 3262–3270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. A. K. Tripathi, W. Sha, V. Shulaev, M. F. Stins, and D. J. Sullivan Jr., “Plasmodium falciparum-infected erythrocytes induce NF-κB regulated inflammatory pathways in human cerebral endothelium,” Blood, vol. 114, no. 19, pp. 4243–4252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Aldieri, D. Atragene, L. Bergandi et al., “Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-κB activation,” FEBS Letters, vol. 552, no. 2-3, pp. 141–144, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. S. P. Hehner, M. Heinrich, P. M. Bork et al., “Sesquiterpene lactones specifically inhibit activation of NF-κB by preventing the degradation of IκB-α and IκB-β,” The Journal of Biological Chemistry, vol. 273, no. 3, pp. 1288–1297, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Ly, A. Knorre, T. J. Schmidt, H. L. Pahl, and I. Merfort, “The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65,” The Journal of Biological Chemistry, vol. 273, no. 50, pp. 33508–33516, 1998. View at Publisher · View at Google Scholar · View at Scopus